Literature DB >> 27503942

Cerebral venous thrombosis associated with thyrotoxicosis, the use of desmopressin and elevated factor VIII/von Willebrand factor.

Waqar Waheed1, Salman Aljerdi1, Barbara Decker1, Mary Cushman2, Robert W Hamill1.   

Abstract

Cerebral venous thrombosis (CVT) is an uncommon disorder associated with diverse processes. We report a patient who, while receiving desmopressin and contraceptive pills (OCP), developed straight sinus thrombosis. Clinical assessment and laboratory investigations revealed untreated hyperthyroidism and a hypercoagulable state, characterised by high levels of von Willebrand factor, factor VIII coagulant activity and IgM cardiolipin antibody. The clinical picture improved with anticoagulation, treatment of hyperthyroidism and discontinuation of OCP and desmopressin. To the best of our knowledge, the association between the use of oral desmopressin and CVT has not been described. The multiple risk factors present in our case were probably additive in increasing the risk of CVT. Although this case represents a rare occurrence, practitioners should be alerted to the possible associations of desmopressin, oral contraceptives and Graves' disease with venous thrombosis. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27503942      PMCID: PMC4986025          DOI: 10.1136/bcr-2016-216584

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  26 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

Review 2.  Cerebral venous thrombosis.

Authors:  Gregory Piazza
Journal:  Circulation       Date:  2012-04-03       Impact factor: 29.690

Review 3.  Elevated factor VIII levels and risk of venous thrombosis.

Authors:  P Vince Jenkins; Orla Rawley; Owen P Smith; James S O'Donnell
Journal:  Br J Haematol       Date:  2012-04-25       Impact factor: 6.998

4.  Cerebral venous thrombosis: clinical outcome and systematic screening of prothrombotic factors.

Authors:  S Cakmak; L Derex; M Berruyer; N Nighoghossian; F Philippeau; P Adeleine; M Hermier; J C Froment; P Trouillas
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

Review 5.  Von Willebrand factor and thrombosis.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Ann Hematol       Date:  2006-03-28       Impact factor: 3.673

6.  Venous thrombosis, oral contraceptives and high factor VIII levels.

Authors:  K W Bloemenkamp; F M Helmerhorst; F R Rosendaal; J P Vandenbroucke
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

7.  The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism.

Authors:  Isabel Tirado; José Mateo; José Manuel Soria; Arturo Oliver; Elisabeth Martínez-Sánchez; Cristina Vallvé; Monserrat Borrell; Teresa Urrutia; Jordi Fontcuberta
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

8.  Thrombosis following desmopressin for uremic bleeding.

Authors:  J J Byrnes; A Larcada; J L Moake
Journal:  Am J Hematol       Date:  1988-05       Impact factor: 10.047

9.  [Venous thrombosis of the lower limbs and pulmonary embolism after desmopressin: a coincidence or a pathogenetic role?].

Authors:  F Pentimone; L Del Corso
Journal:  Clin Ter       Date:  1991 Oct 15-31

10.  Graves' disease associated with cerebrovascular disease and antiphospholipid antibody syndrome.

Authors:  Ines Khochtali; Nadia Hamza; Elyes Gassab; Asma Baba; Maha Kacem; Mahbouba Frih; Sylvia Mahjoub
Journal:  Int J Endocrinol       Date:  2010-09-02       Impact factor: 3.257

View more
  1 in total

1.  Transient water-electrolyte disturbance after hemispherotomy in young infants with epileptic encephalopathy.

Authors:  Takashi Saito; Kenji Sugai; Akio Takahashi; Naoki Ikegaya; Eiji Nakagawa; Masayuki Sasaki; Masaki Iwasaki; Taisuke Otsuki
Journal:  Childs Nerv Syst       Date:  2019-12-16       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.